γ-tocopherolWhat was measured
Measured, with no finding
171 endpoints
Show what was measuredHide what was measured
baseline FMD
no effect, p = 0.05
Baseline FMD, MDA, arginine and ADMA were unaffected by γ-TmT (P>.05)
PMID 22841396 · one of two readings recorded this
baseline plasma ADMA
no effect, p = 0.05
Baseline FMD, MDA, arginine and ADMA were unaffected by γ-TmT (P>.05)
PMID 22841396 · one of two readings recorded this
baseline plasma arginine
no effect, p = 0.05
Baseline FMD, MDA, arginine and ADMA were unaffected by γ-TmT (P>.05)
PMID 22841396 · one of two readings recorded this
baseline plasma MDA
no effect, p = 0.05
Baseline FMD, MDA, arginine and ADMA were unaffected by γ-TmT (P>.05)
PMID 22841396 · one of two readings recorded this
fasting baseline FMD, MDA, arginine and ADMA
no effect, unaffected (P>.05), no per-endpoint estimate
Not recorded as a finding: One sentence covers four endpoints with a single P value and no per-endpoint estimate, and it is the fasting baseline, which would sit beside the postprandial MDA claim on the same node and could be misread as its opposite. Nodes exist for FMD, MDA, ADMA and plasma arginine.
Baseline FMD, MDA, arginine and ADMA were unaffected by γ-TmT (P>.05).
PMID 22841396 · one of two readings recorded this
inflammatory proteins
no effect
Inflammatory proteins were unaffected by glucose ingestion or γ-TmT
PMID 22841396 · one of two readings recorded this
plasma ADMA/arginine ratio after glucose ingestion
decreases, p = 0.05
the ratio of ADMA/arginine increased time-dependently in both trials (P<.05), but to a lesser extent following γ-TmT supplementation (P<.05)
PMID 22841396 · one of two readings recorded this
plasma ADMA/arginine ratio after glucose ingestion
increases, p = 0.05
the ratio of ADMA/arginine increased time-dependently in both trials (P<.05), but to a lesser extent following γ-TmT supplementation (P<.05)
PMID 22841396 · one of two readings recorded this
plasma ADMA/arginine ratio during the 3-h postprandial period
decreases, ratio increased time-dependently in both trials, but to a lesser extent after γ-TmT
Not recorded as a finding: The measured construct is a ratio of ADMA to arginine. The nearest nodes (CAT:outcome/adma, CAT:outcome/arginine-ornithine-ratio) measure ADMA alone or arginine-to-ornithine, so this is a no_outcome_node case.
However, the ratio of ADMA/arginine increased time-dependently in both trials (P<.05), but to a lesser extent following γ-TmT supplementation (P<.05).
PMID 22841396 · one of two readings recorded this
plasma ADMA
no effect
Supplementation of γ-TmT increased (P<.05) plasma γ-T by threefold and γ-carboxyethyl-hydroxychroman by more than ninefold without affecting α-T, glucose, arginine or ADMA
PMID 22841396 · one of two readings recorded this
plasma arginine after glucose ingestion
decreases, p = 0.05
Plasma arginine decreased (P<.05) in both trials to a similar extent regardless of γ-TmT supplementation
PMID 22841396 · one of two readings recorded this
plasma arginine
no effect
Supplementation of γ-TmT increased (P<.05) plasma γ-T by threefold and γ-carboxyethyl-hydroxychroman by more than ninefold without affecting α-T, glucose, arginine or ADMA
PMID 22841396 · one of two readings recorded this
plasma γ-carboxyethyl-hydroxychroman
increases, p = 0.05
Supplementation of γ-TmT increased (P<.05) plasma γ-T by threefold and γ-carboxyethyl-hydroxychroman by more than ninefold without affecting α-T, glucose, arginine or ADMA
PMID 22841396 · one of two readings recorded this
plasma glucose
no effect
Supplementation of γ-TmT increased (P<.05) plasma γ-T by threefold and γ-carboxyethyl-hydroxychroman by more than ninefold without affecting α-T, glucose, arginine or ADMA
PMID 22841396 · one of two readings recorded this
plasma inflammatory proteins (unspecified panel) during the postprandial period
no effect, unaffected by glucose ingestion or γ-TmT
Not recorded as a finding: Agentless-style sentence, and the abstract names no individual protein, so no listed node (for example CAT:outcome/tnf-alpha or interleukin-6) can be chosen.
Inflammatory proteins were unaffected by glucose ingestion or γ-TmT.
PMID 22841396 · one of two readings recorded this
plasma γ-tocopherol
increases, p = 0.05
Supplementation of γ-TmT increased (P<.05) plasma γ-T by threefold and γ-carboxyethyl-hydroxychroman by more than ninefold without affecting α-T, glucose, arginine or ADMA
PMID 22841396 · one of two readings recorded this
postprandial brachial artery flow-mediated dilation (FMD) after a 75 g oral glucose load, 3-h period
FMD decreased 30%-44% after glucose ingestion; maintained with γ-TmT
Not recorded as a finding: The only sentence says FMD 'was maintained with γ-TmT' after falling 30%-44% following glucose ingestion. 'Maintained' reports preservation against a fall, not an increase, and the sentence states no between-trial contrast, so no direction token fits without adding one the sentence does not contain. Node CAT:outcome/flow-mediated-dilation exists.
Postprandial FMD decreased 30%-44% (P<.05) following glucose ingestion, but was maintained with γ-TmT.
PMID 22841396 · one of two readings recorded this
postprandial brachial artery flow-mediated dilation over 3 h after a 75 g oral glucose load
FMD decreased 30%-44% after glucose ingestion (P<.05) in the comparison trial
Not recorded as a finding: flow-mediated-dilation node fits, but 'was maintained with γ-TmT' describes preservation within the supplemented trial and states no between-trial contrast or direction versus the unsupplemented trial; recording increases would be inferred
Postprandial FMD decreased 30%-44% (P<.05) following glucose ingestion, but was maintained with γ-TmT.
PMID 22841396 · one of two readings recorded this
postprandial FMD after glucose ingestion
no effect
Postprandial FMD decreased 30%-44% (P<.05) following glucose ingestion, but was maintained with γ-TmT
PMID 22841396 · one of two readings recorded this
postprandial FMD after glucose ingestion
decreases, p = 0.05
Postprandial FMD decreased 30%-44% (P<.05) following glucose ingestion, but was maintained with γ-TmT
PMID 22841396 · one of two readings recorded this
postprandial increase in MDA after glucose ingestion
decreases
Supplementation of γ-TmT also attenuated postprandial increases in MDA that occurred following glucose ingestion
PMID 22841396 · one of two readings recorded this
postprandial plasma malondialdehyde after glucose ingestion, assay not stated
decreases
Not recorded as a finding: malondialdehyde-circulating node requires the assay (TBARS or HPLC) recorded with each finding and the abstract never states it
Supplementation of γ-TmT also attenuated postprandial increases in MDA that occurred following glucose ingestion.
PMID 22841396 · one of two readings recorded this
brachial artery flow-mediated dilation (FMD)
increases, p = 0.05
Smoking cessation with γ-T-rich supplementation increased FMD responses by 1.3% (P<0.05) beyond smoking cessation alone (4.1 ± 0.6% vs 2.8 ± 0.3%; mean ± SEM)
PMID 24075893 · one of two readings recorded this
plasma cotinine
decreases
Smoking cessation regardless of supplementation similarly decreased plasma cotinine
PMID 24075893 · one of two readings recorded this
plasma malondialdehyde, assay not stated
decreased similarly in both groups (P<0.05)
Not recorded as a finding: The finding sits in a clause that does not name the compound and reports a similar fall in both groups, which is a within-arm change in each arm rather than a stated between-arm contrast. Node CAT:outcome/malondialdehyde-circulating exists.
Although plasma malondialdehyde decreased similarly in both groups (P<0.05), plasma oxidized LDL and urinary F2-isoprostanes were unaffected by smoking cessation or γ-T-rich supplementation.
PMID 24075893 · both readings recorded this
plasma malondialdehyde
decreases, p = 0.05
Although plasma malondialdehyde decreased similarly in both groups (P<0.05)
PMID 24075893 · one of two readings recorded this
plasma myeloperoxidase vs FMD
decreases, p = 0.05
these were inversely related to FMD (P<0.05; R=-0.46 and -0.37, respectively)
PMID 24075893 · one of two readings recorded this
plasma myeloperoxidase
decreases, p = 0.05
Plasma TNF-α and myeloperoxidase decreased (P<0.05) only in those receiving γ-T-rich supplements
PMID 24075893 · one of two readings recorded this
plasma oxidized LDL and urinary F2-isoprostanes, assay not stated
no effect, unaffected by smoking cessation or γ-T-rich supplementation
Not recorded as a finding: No listed outcome node for oxidized LDL or urinary F2-isoprostanes.
Although plasma malondialdehyde decreased similarly in both groups (P<0.05), plasma oxidized LDL and urinary F2-isoprostanes were unaffected by smoking cessation or γ-T-rich supplementation.
PMID 24075893 · one of two readings recorded this
plasma oxidized LDL
no effect
plasma oxidized LDL and urinary F2-isoprostanes were unaffected by smoking cessation or γ-T-rich supplementation
PMID 24075893 · one of two readings recorded this
plasma TNF-α, immunoassay not stated
decreases
Not recorded as a finding: the only sentence reports a within-arm decrease 'only in those receiving' the supplement, not a between-arm contrast (within_arm_only); the tnf-alpha node would otherwise fit
Plasma TNF-α and myeloperoxidase decreased (P<0.05) only in those receiving γ-T-rich supplements and these were inversely related to FMD (P<0.05; R=-0.46 and -0.37, respectively).
PMID 24075893 · both readings recorded this
plasma TNF-α vs FMD
decreases, p = 0.05
these were inversely related to FMD (P<0.05; R=-0.46 and -0.37, respectively)
PMID 24075893 · one of two readings recorded this
plasma TNF-α
decreases, p = 0.05
Plasma TNF-α and myeloperoxidase decreased (P<0.05) only in those receiving γ-T-rich supplements
PMID 24075893 · one of two readings recorded this
plasma γ-tocopherol
increases, p = 0.05
γ-T-rich supplementation increased plasma γ-T by seven times and its urinary metabolite γ-carboxyethyl hydroxychroman by nine times (P<0.05)
PMID 24075893 · one of two readings recorded this
urinary γ-carboxyethyl hydroxychroman
increases, p = 0.05
γ-T-rich supplementation increased plasma γ-T by seven times and its urinary metabolite γ-carboxyethyl hydroxychroman by nine times (P<0.05)
PMID 24075893 · one of two readings recorded this
urinary F2-isoprostanes
no effect
plasma oxidized LDL and urinary F2-isoprostanes were unaffected by smoking cessation or γ-T-rich supplementation
PMID 24075893 · one of two readings recorded this
FEV1 and FEV1/FVC
no effect
no clinically or statistically significant changes were seen in FEV1 or FEV1/FVC from measurements taken during the initial baseline visit
PMID 28736267 · one of two readings recorded this
induced sputum neutrophil percentage (%PMNs, cytocentrifuge differential with modified Wright stain), change from post-treatment to 6 h and 24 h after inhaled LPS challenge (primary endpoint); induced sputum eosinophils (%, and per mg sputum) after 14 days of treatment, pre-challenge (primary endpoint); sputum total mucins and MUC5AC by refractometry and mass spectrometry; mucociliary clearance by 99mTc sulfur colloid gamma scintigraphy; sputum cytokines IL-1β, IL-6 and IL-8 by multiplex immunoassay
decreases, γT attenuated the LPS-induced rise in sputum %PMNs versus placebo at 6 h (p=0.04) and at 24 h (p=0.02), p = 0.04
Not recorded as a finding: this platform holds no node for the endpoint
Linear mixed modeling demonstrated that γT treatment (compared to placebo) significantly attenuated sputum %PMNs at both 6 (p=0.04) and 24 hours (p=0.02) after LPS challenge.
PMID 28736267 · one of two readings recorded this
LPS-induced change in sputum PMNs per mg
no effect, p = 0.2
PMNs/mg Δ 236.2 ± 692.7 SD, p=0.2
PMID 28736267 · one of two readings recorded this
LPS-induced change in sputum PMNs per mg
increases, p = 0.01
PMNs/mg Δ 384.1 ± 531.2 SD, p<0.01
PMID 28736267 · one of two readings recorded this
LPS-induced change in sputum %PMNs
increases, p = 0.04
% PMNS Δ 11.7% ± 20.7 SD, p=0.04
PMID 28736267 · one of two readings recorded this
LPS-induced change in sputum %PMNs
increases, p = 0.01
%PMNs: Δ 20.1% ± 16.5 SD, p<0.01
PMID 28736267 · one of two readings recorded this
LPS-induced sputum inflammatory cytokines
no effect
we did not detect a significant γT treatment effect on LPS-induced inflammatory cytokine concentrations in sputum following LPS challenge
PMID 28736267 · one of two readings recorded this
LPS-induced sputum %PMNs, γT vs placebo
decreases, p = 0.02
Linear mixed modeling demonstrated that γT treatment (compared to placebo) significantly attenuated sputum %PMNs at both 6 (p=0.04) and 24 hours (p=0.02) after LPS challenge
PMID 28736267 · one of two readings recorded this
LPS-induced sputum %PMNs, γT vs placebo
decreases, p = 0.04
Linear mixed modeling demonstrated that γT treatment (compared to placebo) significantly attenuated sputum %PMNs at both 6 (p=0.04) and 24 hours (p=0.02) after LPS challenge
PMID 28736267 · one of two readings recorded this
mucociliary clearance (MCC) after LPS challenge
no effect, p = 0.6
there was no such slowing of MCC by LPS challenge during active treatment (MCC = 20.2 ± 8.0% post-challenge vs. 21.4 ± 9.7% post-treatment, p=0.6)
PMID 28736267 · one of two readings recorded this
mucociliary clearance (MCC) after LPS challenge
decreases, p = 0.01
MCC was significantly slowed following LPS challenge compared to post-treatment measurements for the placebo treatment period (MCC = 16.3 ± 9.3% post-challenge vs. 21.4 ± 6.9% post-treatment, p < 0.01)
PMID 28736267 · one of two readings recorded this
post-treatment induced-sputum percentage eosinophils and eosinophils per mg sputum (primary endpoint, cytocentrifuge differential), after 14 days of a gamma-tocopherol-enriched supplement (2 geltabs once daily, each 612 mg gamma-tocopherol, 7 mg alpha-tocopherol, 28 mg beta-tocopherol, 8 mg delta-tocopherol; Callion Pharma; tocopherols only) versus safflower oil placebo in mild asthma; also measured: LPS-induced sputum neutrophilia, sputum mucins and MUC5AC, mucociliary clearance by gamma scintigraphy, sputum cytokines
decreases, post-treatment sputum %eosinophils p=0.04; eosinophils/mg of sputum p=0.01, p = 0.04
Not recorded as a finding: this platform holds no node for the endpoint
Using the linear mixed model approach, we found that γT treatment significantly reduced post-treatment sputum %eosinophils (p=0.04) and eosinophils/mg of sputum (p=0.01) compared to placebo.
PMID 28736267 · one of two readings recorded this
post-treatment sputum eosinophils per mg
decreases, p = 0.01
γT treatment significantly reduced post-treatment sputum %eosinophils (p=0.04) and eosinophils/mg of sputum (p=0.01)
PMID 28736267 · one of two readings recorded this
post-treatment sputum %eosinophils
decreases, p = 0.04
γT treatment significantly reduced post-treatment sputum %eosinophils (p=0.04) and eosinophils/mg of sputum (p=0.01)
PMID 28736267 · one of two readings recorded this
post-treatment sputum MUC5AC content
decreases, p = 0.0001
γT treatment significantly reduced post-treatment total mucins (p=0.03) and MUC5AC content (p<0.0001) compared to placebo
PMID 28736267 · one of two readings recorded this
post-treatment total sputum mucins
decreases, p = 0.03
γT treatment significantly reduced post-treatment total mucins (p=0.03) and MUC5AC content (p<0.0001) compared to placebo
PMID 28736267 · one of two readings recorded this
PT, aPTT and INR
no effect
No significant change in PT, aPTT, or INR was observed
PMID 28736267 · one of two readings recorded this
regional deposition indices (C/P, skew) and 24-hour retention
no effect
There were no differences in regional deposition indices (C/P or skew) nor in 24-hour retention between post-treatment and post-challenge measurements for either treatment period
PMID 28736267 · one of two readings recorded this
serum γ-CEHC
increases, p = 0.0001
Serum γT and γ-CEHC concentrations rose significantly from baseline values in the active treatment group only (p<0.0001 for both)
PMID 28736267 · one of two readings recorded this
serum γ-tocopherol
increases, p = 0.0001
Serum γT and γ-CEHC concentrations rose significantly from baseline values in the active treatment group only (p<0.0001 for both)
PMID 28736267 · one of two readings recorded this
sputum eosinophilia following LPS challenge
no effect
There was no effect of inhaled LPS challenge or γT treatment on any measure of sputum eosinophilia following LPS challenge
PMID 28736267 · one of two readings recorded this
sputum IL-1β after LPS challenge
no effect, p = 0.07
no significant LPS-induced increase was observed during the active treatment period (p=0.07 and p=0.40, respectively)
PMID 28736267 · one of two readings recorded this
sputum IL-1β after LPS challenge
increases, p = 0.002
During the placebo period, sputum IL-1β and IL-8 concentrations were significantly increased 6 hours post-LPS challenge compared to post-treatment values (p=0.002 and p=0.01, respectively)
PMID 28736267 · one of two readings recorded this
sputum IL-6 after LPS challenge
no effect
There was no significant LPS-induced change in sputum IL-6 concentration during either treatment period
PMID 28736267 · one of two readings recorded this
sputum IL-8 after LPS challenge
no effect, p = 0.4
no significant LPS-induced increase was observed during the active treatment period (p=0.07 and p=0.40, respectively)
PMID 28736267 · one of two readings recorded this
sputum IL-8 after LPS challenge
increases, p = 0.01
During the placebo period, sputum IL-1β and IL-8 concentrations were significantly increased 6 hours post-LPS challenge compared to post-treatment values (p=0.002 and p=0.01, respectively)
PMID 28736267 · one of two readings recorded this
sputum MUC5AC concentration after LPS challenge
no effect
We found no significant difference in MUC5AC concentrations between the treatment groups at the same time point (data not shown)
PMID 28736267 · one of two readings recorded this
sputum MUC5AC content after LPS challenge
increases, p = 0.0004
MUC5AC content was significantly increased from post-treatment levels in both treatment groups 6 hours after inhaled LPS challenge [p=0.001 (placebo), p=0.0004 (active)]
PMID 28736267 · one of two readings recorded this
sputum MUC5AC content after LPS challenge
increases, p = 0.001
MUC5AC content was significantly increased from post-treatment levels in both treatment groups 6 hours after inhaled LPS challenge [p=0.001 (placebo), p=0.0004 (active)]
PMID 28736267 · one of two readings recorded this
sputum %PMNs after LPS challenge
increases, p = 0.003
Inhaled LPS challenge significantly increased sputum percent neutrophils (%PMNs) (p=0.003) and neutrophils per mg (PMNs/mg) of sputum (p=0.01) at 6 hours compared to post-treatment sputum during the placebo period
PMID 28736267 · one of two readings recorded this
sputum PMNs per mg after LPS challenge
increases, p = 0.01
Inhaled LPS challenge significantly increased sputum percent neutrophils (%PMNs) (p=0.003) and neutrophils per mg (PMNs/mg) of sputum (p=0.01) at 6 hours compared to post-treatment sputum during the placebo period
PMID 28736267 · one of two readings recorded this
total sputum mucins after LPS challenge
decreases, p = 0.03
we detected significantly less total sputum mucins during the active treatment period compared to placebo (=0.03)
PMID 28736267 · one of two readings recorded this
change in LPS-induced sputum neutrophilia (post-challenge % sputum PMNs minus post-treatment % sputum PMNs) after inhaled endotoxin challenge (20,000 EU), gamma-tocopherol-enriched supplement 1200 mg daily for 7 days (healthy volunteers) or 14 days (mild asthmatics) versus safflower oil placebo, pooled post hoc across two crossover trials
decreases
Not recorded as a finding: this platform holds no node for the endpoint
Active treatment with γT attenuated sputum PMN recruitment following inhaled LPS challenge in both HV and AV.
PMID 30660638 · one of two readings recorded this
effect of γT on LPS-induced sputum PMN recruitment, effect modification by categorical BMI (model with BMI, GSTM1 and asthma)
no effect, p = 0.44
including categorical BMI, GSTM1 genotype, and presence of asthma as independent variables yielded similar results [p=0.44 (−17.43, 7.46), 0.51 (−15.49, 7.57), 0.69 (−14.40, 9.49), respectively]
PMID 30660638 · one of two readings recorded this
effect of γT on LPS-induced sputum PMN recruitment, effect modification by categorical BMI
no effect, p = 0.6
no effect modification by categorical BMI (<25 or ≥25) [p=0.60 (−14.24, 8.13); Figure 2a]
PMID 30660638 · one of two readings recorded this
effect of γT on LPS-induced sputum PMN recruitment, effect modification by GSTM1 genotype (model with BMI, GSTM1 and asthma)
no effect, p = 0.51
including categorical BMI, GSTM1 genotype, and presence of asthma as independent variables yielded similar results [p=0.44 (−17.43, 7.46), 0.51 (−15.49, 7.57), 0.69 (−14.40, 9.49), respectively]
PMID 30660638 · one of two readings recorded this
effect of γT on LPS-induced sputum PMN recruitment, effect modification by GSTM1 genotype
no effect, p = 0.4
or GSTM1 genotype [p=0.40 (−16.02, 6.20); Figure 2b]
PMID 30660638 · one of two readings recorded this
effect of γT on LPS-induced sputum PMN recruitment, effect modification by presence of asthma (model with BMI, GSTM1 and asthma)
no effect, p = 0.69
including categorical BMI, GSTM1 genotype, and presence of asthma as independent variables yielded similar results [p=0.44 (−17.43, 7.46), 0.51 (−15.49, 7.57), 0.69 (−14.40, 9.49), respectively]
PMID 30660638 · one of two readings recorded this
LPS-induced sputum neutrophilia, calculated as post-challenge % sputum PMNs minus post-treatment % sputum PMNs, 6 h after inhaled LPS (20,000 endotoxin units), in healthy volunteers and mild asthmatics combined, and whether BMI or GSTM1 genotype modified the γT effect (post hoc pooled analysis of two crossover trials)
decreases
Not recorded as a finding: this platform holds no node for the endpoint
Active treatment with γT attenuated sputum PMN recruitment following inhaled LPS challenge in both HV and AV.
PMID 30660638 · one of two readings recorded this
LPS-induced sputum PMN recruitment, effect modification by categorical BMI
no effect, p = 0.67
there was no effect modification by categorical BMI [p=0.67 (−14.25, 9.12)]
PMID 30660638 · one of two readings recorded this
LPS-induced sputum PMN recruitment, effect modification by GSTM1 genotype
no effect, p = 0.33
GSTM1 genotype [p=0.33 (−18.25, 5.95)] on sputum PMN recruitment following inhaled LPS challenge
PMID 30660638 · one of two readings recorded this
LPS-induced sputum PMN recruitment
decreases
Active treatment with γT attenuated sputum PMN recruitment following inhaled LPS challenge in both HV and AV
PMID 30660638 · one of two readings recorded this
LPS-induced sputum PMN recruitment
decreases
Active treatment with γT attenuated sputum PMN recruitment following inhaled LPS challenge in both HV and AV
PMID 30660638 · one of two readings recorded this
central region Ave30Clr clearance
unclear, p = 0.07
central Ave30Clr: 12.6% [± 9.2% SD] baseline vs 9.8% [± 8.5%] post-O3, p=0.07
PMID 32727225 · one of two readings recorded this
central region Ave30Clr clearance
no effect, p = 0.86
12.6% [± 9.2%] baseline vs 12.1% [± 6.8%] post-O3, p=0.86
PMID 32727225 · one of two readings recorded this
change in induced-sputum percentage neutrophils (PMN) from before to 6 hours after a 3-hour 0.25 ppm ozone challenge, after a 4-dose gamma-tocopherol-enriched supplement (89.5% d-gamma tocopherol, total tocopherols 93.2%, about 600 mg per geltab, two geltabs every 12 h) versus safflower-oil placebo
mean increase in sputum %PMN 36.5 percentage points following placebo versus 34.1 following gamma tocopherol
Not recorded as a finding: this platform holds no node for the endpoint
However, γT supplementation did not attenuate O3-induced neutrophilic airway inflammation compared to placebo (mean increase in sputum %PMN of 36.5 percentage points [± 20.2] following placebo versus 34.1 percentage points [± 20.2] following γT, p>0.9).
PMID 32727225 · one of two readings recorded this
induced sputum neutrophil percentage (%PMN) increase from pre-ozone to 6 h after 0.25 ppm ozone for 3 h; pre-ozone induced sputum eosinophil percentage; sputum cytokines IL-1β, IL-6, IL-8 and TNFα by V-PLEX immunoassay; mucociliary clearance of inhaled 99mTc sulfur colloid by gamma scintigraphy (whole lung and central region); in 7 volunteers for the sputum endpoints
no effect, mean ozone-induced rise in sputum %PMN 36.5 percentage points after placebo versus 34.1 after γT; no attenuation
Not recorded as a finding: this platform holds no node for the endpoint
However, γT supplementation did not attenuate O3-induced neutrophilic airway inflammation compared to placebo (mean increase in sputum %PMN of 36.5 percentage points [± 20.2] following placebo versus 34.1 percentage points [± 20.2] following γT, p>0.9).
PMID 32727225 · one of two readings recorded this
O3-induced increase in sputum %PMN
no effect, p = 0.9
mean increase in sputum %PMN of 36.5 percentage points [± 20.2] following placebo versus 34.1 percentage points [± 20.2] following γT, p>0.9
PMID 32727225 · one of two readings recorded this
pre-O3 sputum eosinophils
no effect, p = 0.56
mean of 2.2% sputum eosinophils [± 3.7 SD] following placebo treatment and 3.4% sputum eosinophils [± 4.3] following γT treatment, p=0.56
PMID 32727225 · one of two readings recorded this
sputum cytokines after O3
no effect
no difference in sputum cytokines following γT supplementation compared to placebo (data not shown)
PMID 32727225 · one of two readings recorded this
sputum inflammatory cytokines (IL-1β, IL-6, IL-8, TNFα) change from baseline after O3
no effect
We found no significant change in sputum inflammatory cytokines (Interleukin (IL)-1 β, IL-6, IL-8 and TNFα) from baseline following O3 exposure
PMID 32727225 · one of two readings recorded this
sputum percentage of eosinophils after O3
no effect
with no significant effect on sputum percentage of eosinophils
PMID 32727225 · one of two readings recorded this
sputum percentage of neutrophils after O3
increases
O3 exposure significantly increased sputum percentage of neutrophils during both the placebo and γT treatment periods
PMID 32727225 · one of two readings recorded this
whole lung average 120 minute clearance (Ave120Clr)
no effect
mean average 120 minute clearance (Ave120Clr) of 21% (± 7% SD) at baseline, 21% (± 7%) post-O3 during placebo, and 23% (± 7%) post-O3 during γT treatment
PMID 32727225 · one of two readings recorded this
24-h cumulative urinary sodium excretion (mEq), luteal phase
mean difference 10.6 mEq (95% CI -0.1, 21.4, power 55%), p = 0.052
Not recorded as a finding: no outcome node for urinary sodium excretion (serum-sodium is a different matrix); result also not significant with no absence stated in words
In the luteal phase, the mean difference in 24-h urinary sodium excretion between γ-Toc and placebo intake was 10.6 mEq (95% CI: -0.1, 21.4, p = 0.052, power 55%).
PMID 37118716 · one of two readings recorded this
24-h urinary sodium excretion
unclear, p = 0.052
In the luteal phase, the mean difference in 24-h urinary sodium excretion between γ-Toc and placebo intake was 10.6 mEq (95% CI: -0.1, 21.4, p = 0.052, power 55%)
PMID 37118716 · one of two readings recorded this
cumulative 24-h urinary sodium excretion (mEq), luteal phase, 25 participants
mean difference 10.6 mEq (95% CI -0.1, 21.4), power 55%, p = 0.052
Not recorded as a finding: No outcome node for urinary sodium excretion (CAT:outcome/serum-sodium is serum). The estimate straddles zero and the sentence states no direction word.
In the luteal phase, the mean difference in 24-h urinary sodium excretion between γ-Toc and placebo intake was 10.6 mEq (95% CI: -0.1, 21.4, p = 0.052, power 55%).
PMID 37118716 · one of two readings recorded this
cumulative urinary potassium excretion
no effect
There was no significant between-supplement difference in cumulative urinary potassium excretion (data not shown)
PMID 37118716 · one of two readings recorded this
cumulative urinary sodium excretion
increases, p = 0.026
p-value vs. placebo intake | 0.026 | 0.630
PMID 37118716 · one of two readings recorded this
cumulative urinary sodium excretion
no effect, p = 0.63
p-value vs. placebo intake | 0.026 | 0.630
PMID 37118716 · one of two readings recorded this
cumulative urinary sodium excretion
no effect, p = 0.464
p-value vs. placebo intake | 0.052 | 0.464
PMID 37118716 · one of two readings recorded this
cumulative urinary sodium excretion
γ-Toc intake | 145.7 ± 9.4 | 346.0 ± 16.7
PMID 37118716 · one of two readings recorded this
cumulative urinary sodium excretion
γ-Toc intake | 145.7 ± 9.4 | 346.0 ± 16.7
PMID 37118716 · one of two readings recorded this
cumulative urinary sodium excretion
γ-Toc intake | 151.1 ± 7.7 | 353.1 ± 13.6
PMID 37118716 · one of two readings recorded this
cumulative urinary sodium excretion
γ-Toc intake | 151.1 ± 7.7 | 353.1 ± 13.6
PMID 37118716 · one of two readings recorded this
cumulative urinary sodium excretion
Urinary sodium excretion (mEq) | Follicular phase | 155.2 ± 9.7 | 383.2 ± 13.7
PMID 37118716 · one of two readings recorded this
cumulative urinary sodium excretion
Urinary sodium excretion (mEq) | Follicular phase | 155.2 ± 9.7 | 383.2 ± 13.7
PMID 37118716 · one of two readings recorded this
cumulative urinary sodium excretion
Urinary sodium excretion (mEq) | Follicular phase | 143.9 ± 8.0 | 359.3 ± 13.6
PMID 37118716 · one of two readings recorded this
cumulative urinary sodium excretion
Urinary sodium excretion (mEq) | Follicular phase | 143.9 ± 8.0 | 359.3 ± 13.6
PMID 37118716 · one of two readings recorded this
cumulative urinary sodium excretion
Placebo intake | 129.5 ± 8.6 | 334.7 ± 17.3
PMID 37118716 · one of two readings recorded this
cumulative urinary sodium excretion
Placebo intake | 129.5 ± 8.6 | 334.7 ± 17.3
PMID 37118716 · one of two readings recorded this
cumulative urinary sodium excretion
Placebo intake | 139.4 ± 7.1 | 343.8 ± 13.4
PMID 37118716 · one of two readings recorded this
cumulative urinary sodium excretion
Placebo intake | 139.4 ± 7.1 | 343.8 ± 13.4
PMID 37118716 · one of two readings recorded this
cumulative urinary sodium excretion
unclear, p = 0.001
p-value vs. luteal phase | 0.001 | < 0.001
PMID 37118716 · one of two readings recorded this
cumulative urinary sodium excretion
unclear, p = 0.001
p-value vs. luteal phase | 0.001 | < 0.001
PMID 37118716 · one of two readings recorded this
cumulative urinary sodium excretion
no effect, p = 0.587
p-value vs. luteal phase | 0.587 | 0.250
PMID 37118716 · one of two readings recorded this
cumulative urinary sodium excretion
no effect, p = 0.25
p-value vs. luteal phase | 0.587 | 0.250
PMID 37118716 · one of two readings recorded this
cumulative urine volume (mL) over 24 h and 48 h
no effect
Not recorded as a finding: Node CAT:outcome/urine-output fits, but the only sentence says 'between-supplement' and never names γ-Toc, so it does not support the claim on its own and the arm is only resolved from Methods.
There was no significant between-supplement difference in urine volume (Table 2 a).
PMID 37118716 · one of two readings recorded this
cumulative urine volume
no effect, p = 0.591
p-value vs. placebo intake | 0.591 | 0.436
PMID 37118716 · one of two readings recorded this
cumulative urine volume
no effect, p = 0.436
p-value vs. placebo intake | 0.591 | 0.436
PMID 37118716 · one of two readings recorded this
cumulative urine volume
no effect, p = 0.734
p-value vs. placebo intake | 0.734 | 0.981
PMID 37118716 · one of two readings recorded this
cumulative urine volume
no effect, p = 0.981
p-value vs. placebo intake | 0.734 | 0.981
PMID 37118716 · one of two readings recorded this
cumulative urine volume
γ-Toc intake | 1433 ± 90 | 3225 ± 158
PMID 37118716 · one of two readings recorded this
cumulative urine volume
γ-Toc intake | 1433 ± 90 | 3225 ± 158
PMID 37118716 · one of two readings recorded this
cumulative urine volume
γ-Toc intake | 1480 ± 65 | 3305 ± 119
PMID 37118716 · one of two readings recorded this
cumulative urine volume
γ-Toc intake | 1480 ± 65 | 3305 ± 119
PMID 37118716 · one of two readings recorded this
cumulative urine volume
Urine volume (mL) | Follicular phase | 1563 ± 88 | 3526 ± 136
PMID 37118716 · one of two readings recorded this
cumulative urine volume
Urine volume (mL) | Follicular phase | 1563 ± 88 | 3526 ± 136
PMID 37118716 · one of two readings recorded this
cumulative urine volume
Urine volume (mL) | Follicular phase | 1478 ± 70 | 3399 ± 112
PMID 37118716 · one of two readings recorded this
cumulative urine volume
Urine volume (mL) | Follicular phase | 1478 ± 70 | 3399 ± 112
PMID 37118716 · one of two readings recorded this
cumulative urine volume
Placebo intake | 1369 ± 87 | 3235 ± 162
PMID 37118716 · one of two readings recorded this
cumulative urine volume
Placebo intake | 1369 ± 87 | 3235 ± 162
PMID 37118716 · one of two readings recorded this
cumulative urine volume
Placebo intake | 1450 ± 67 | 3283 ± 116
PMID 37118716 · one of two readings recorded this
cumulative urine volume
Placebo intake | 1450 ± 67 | 3283 ± 116
PMID 37118716 · one of two readings recorded this
cumulative urine volume
unclear, p = 0.039
p-value vs. luteal phase | 0.039 | 0.031
PMID 37118716 · one of two readings recorded this
cumulative urine volume
unclear, p = 0.031
p-value vs. luteal phase | 0.039 | 0.031
PMID 37118716 · one of two readings recorded this
cumulative urine volume
no effect, p = 0.746
p-value vs. luteal phase | 0.746 | 0.309
PMID 37118716 · one of two readings recorded this
cumulative urine volume
no effect, p = 0.309
p-value vs. luteal phase | 0.746 | 0.309
PMID 37118716 · one of two readings recorded this
days from E-D1 to next menstrual onset
no effect
During γ-Toc and placebo intake, E-D1 in the luteal phase was 6.0 ± 0.5 days and 7.2 ± 0.5 days, respectively, before the onset of the next menstrual period
PMID 37118716 · one of two readings recorded this
MDQ arousal
no effect, p = 0.195
Arousal | 2.1 ± 0.7 | 1.3 ± 0.5 | 0.195
PMID 37118716 · one of two readings recorded this
MDQ autonomic reactions
increases, p = 0.004
Autonomic reactions | 0.2 ± 0.2 | 1.1 ± 0.4 | 0.004
PMID 37118716 · one of two readings recorded this
MDQ behavior change
increases, p = 0.001
Behavior change | 2.0 ± 0.6 | 5.6 ± 1.0 | < 0.001
PMID 37118716 · one of two readings recorded this
MDQ concentration
no effect, p = 0.079
During the luteal phase, γ-Toc intake resulted in non-significantly lower MDQ scores for “concentration” than placebo intake (p = 0.079)
PMID 37118716 · one of two readings recorded this
MDQ concentration
increases, p = 0.006
The luteal phase showed significantly higher MDQ scores for “concentration” and “negative affect” than the follicular phase (p = 0.006 and p = 0.049, respectively
PMID 37118716 · one of two readings recorded this
MDQ control
increases, p = 0.005
Control | 0.3 ± 0.2 | 1.8 ± 0.6 | 0.005
PMID 37118716 · one of two readings recorded this
MDQ impaired concentration
increases, p = 0.003
Impaired concentration | 2.1 ± 0.8 | 5.6 ± 1.1 | 0.003
PMID 37118716 · one of two readings recorded this
MDQ negative affect
increases, p = 0.001
Negative affect | 0.8 ± 0.4 | 5.4 ± 1.0 | < 0.001
PMID 37118716 · one of two readings recorded this
MDQ negative affect
increases, p = 0.049
The luteal phase showed significantly higher MDQ scores for “concentration” and “negative affect” than the follicular phase (p = 0.006 and p = 0.049, respectively
PMID 37118716 · one of two readings recorded this
MDQ pain
increases, p = 0.001
Pain | 1.9 ± 0.5 | 6.9 ± 1.1 | < 0.001
PMID 37118716 · one of two readings recorded this
MDQ water retention
increases, p = 0.001
Water retention | 2.1 ± 0.4 | 9.6 ± 0.8 | < 0.001
PMID 37118716 · one of two readings recorded this
morning serum progesterone and estradiol
no effect
There were no significant between-supplement differences in the morning serum progesterone and estradiol levels on E-D1 in the luteal phase
PMID 37118716 · one of two readings recorded this
plasma aldosterone
no effect, p = 0.199
E-D1 | 189.3 ± 16.8 | 317.6 ± 29.1 | < 0.001 | 278.3 ± 34.9 | 0.199
PMID 37118716 · one of two readings recorded this
plasma aldosterone
increases, p = 0.001
E-D1 | 189.3 ± 16.8 | 317.6 ± 29.1 | < 0.001 | 278.3 ± 34.9 | 0.199
PMID 37118716 · one of two readings recorded this
plasma ANP
no effect, p = 0.059
E-D1 | 27.0 ± 2.8 | 21.9 ± 1.6 | 0.041 | 25.7 ± 2.3 | 0.059
PMID 37118716 · one of two readings recorded this
plasma ANP
decreases, p = 0.041
E-D1 | 27.0 ± 2.8 | 21.9 ± 1.6 | 0.041 | 25.7 ± 2.3 | 0.059
PMID 37118716 · one of two readings recorded this
plasma atrial natriuretic peptide (ANP), pg/mL, E-D3 morning
increases, significantly increased with γ-Toc versus placebo in E-D3 mornings; no estimate in the sentence
Not recorded as a finding: No outcome node for plasma ANP.
In the luteal phase, γ-Toc intake significantly increased plasma ANP levels in E-D3 mornings, compared with placebo intake.
PMID 37118716 · one of two readings recorded this
plasma atrial natriuretic peptide (ANP), pg/mL
increases
Not recorded as a finding: no outcome node for plasma ANP; assay not stated
In the luteal phase, γ-Toc intake significantly increased plasma ANP levels in E-D3 mornings, compared with placebo intake.
PMID 37118716 · one of two readings recorded this
plasma γ-CEHC
increases, p = 0.001
γ-Toc intake significantly increased plasma γ-CEHC levels in the mornings of E-D1 (0.08 ± 0.02 μM vs. 2.87 ± 0.29 μM, p < 0.001)
PMID 37118716 · one of two readings recorded this
plasma γ-tocopherol
increases, p = 0.001
γ-Toc intake significantly increased plasma γ-Toc levels in the mornings of E-D1 (2.5 ± 0.2 μM vs. 16.3 ± 1.1 μM, p < 0.001)
PMID 37118716 · one of two readings recorded this
rate of change in plasma volume
no effect
Moreover, there was no significant between-supplement difference in the rate of change in plasma volume from E-D1 morning to E-D3 morning
PMID 37118716 · one of two readings recorded this
serum sodium, potassium, osmolality, protein, hemoglobin and hematocrit
no effect
There were no significant between-supplement differences in serum sodium, serum potassium, osmolality, protein concentration, hemoglobin, and hematocrit levels in the mornings of E-D1 and E-D3
PMID 37118716 · one of two readings recorded this
serum sodium, serum potassium, osmolality, protein, haemoglobin and haematocrit, mornings of E-D1 and E-D3
no effect, no significant between-supplement differences; no estimates in the sentence
Not recorded as a finding: Nodes CAT:outcome/serum-sodium, serum-potassium, blood-haemoglobin and haematocrit exist, but the sentence covers six analytes in one statement with no estimates and says 'between-supplement' without naming γ-Toc, so it does not support a claim on its own.
There were no significant between-supplement differences in serum sodium, serum potassium, osmolality, protein concentration, hemoglobin, and hematocrit levels in the mornings of E-D1 and E-D3.
PMID 37118716 · one of two readings recorded this
thigh circumference in the standing position, tape, mornings of E-D2 and E-D3
decreases, significantly lower with γ-Toc than placebo; no estimate in the sentence
Not recorded as a finding: No outcome node for limb circumference (CAT:outcome/waist-circumference is waist girth only).
In the mornings of E-D2 and E-D3, thigh circumference was significantly lower with γ-Toc intake than with placebo intake (Fig. [i] and c [ii]).
PMID 37118716 · one of two readings recorded this
thigh circumference, tape measure in standing position
decreases
Not recorded as a finding: no outcome node for limb circumference
In addition, γ-Toc intake resulted in a significantly lower thigh circumference than the placebo intake.
PMID 37118716 · one of two readings recorded this
thigh circumference
decreases
In the mornings of E-D2 and E-D3, thigh circumference was significantly lower with γ-Toc intake than with placebo intake
PMID 37118716 · one of two readings recorded this
VAS abdominal bloating
increases
During placebo intake, the VAS scores for “breast tenderness/soreness” (Supplementary Fig. 1 c), “abdominal bloating” (Supplementary Fig. 1 d), and “irritability/anger” (Supplementary Fig. 1 i) were significantly higher in the luteal phase than in the follicular phase
PMID 37118716 · one of two readings recorded this
VAS breast tenderness/soreness
increases
During placebo intake, the VAS scores for “breast tenderness/soreness” (Supplementary Fig. 1 c), “abdominal bloating” (Supplementary Fig. 1 d), and “irritability/anger” (Supplementary Fig. 1 i) were significantly higher in the luteal phase than in the follicular phase
PMID 37118716 · one of two readings recorded this
VAS fatigue
decreases
the VAS scores for “fatigue” (Supplementary Fig. 2 g) and “irritability/angry” (Supplementary Fig. 2 i) were significantly lower with γ-Toc intake than with placebo intake
PMID 37118716 · one of two readings recorded this
VAS fatigue
unclear, p = 0.075
The mean differences in scores for “heavy legs,” “fatigue,” and “irritability/anger” on E-D2 were -7.9 mm (95% confidence interval (CI): -16.2, 0.4, p = 0.062, power 46%), -8.7 mm (95% CI: -18.4, 0.9, p = 0.075, power 43%), and -5.5 mm (95% CI: -12.0, 1.1, p = 0.097, power 38%)
PMID 37118716 · one of two readings recorded this
VAS heavy legs
unclear, p = 0.05
there were almost significant between-supplement differences in the VAS scores for “heavy legs” (p = 0.050
PMID 37118716 · one of two readings recorded this
VAS heavy legs
unclear, p = 0.062
The mean differences in scores for “heavy legs,” “fatigue,” and “irritability/anger” on E-D2 were -7.9 mm (95% confidence interval (CI): -16.2, 0.4, p = 0.062, power 46%), -8.7 mm (95% CI: -18.4, 0.9, p = 0.075, power 43%), and -5.5 mm (95% CI: -12.0, 1.1, p = 0.097, power 38%)
PMID 37118716 · one of two readings recorded this
VAS irritability/anger
decreases
the VAS scores for “fatigue” (Supplementary Fig. 2 g) and “irritability/angry” (Supplementary Fig. 2 i) were significantly lower with γ-Toc intake than with placebo intake
PMID 37118716 · one of two readings recorded this
VAS irritability/anger
increases
During placebo intake, the VAS scores for “breast tenderness/soreness” (Supplementary Fig. 1 c), “abdominal bloating” (Supplementary Fig. 1 d), and “irritability/anger” (Supplementary Fig. 1 i) were significantly higher in the luteal phase than in the follicular phase
PMID 37118716 · one of two readings recorded this
VAS scores (100-mm) for the single items 'fatigue' and 'irritability/anger' within a 10-item premenstrual symptom VAS, whole evaluation period
decreases, significantly lower with γ-Toc than placebo; no estimate in the sentence
Not recorded as a finding: Node CAT:outcome/subjective-fatigue needs a named validated self-report instrument measuring fatigue specifically; the paper uses one item of a 10-item premenstrual-symptom VAS, so this is endpoint_near_miss. Irritability/anger has no node.
Moreover, the VAS scores for “fatigue” (Supplementary Fig. 2 g) and “irritability/angry” (Supplementary Fig. 2 i) were significantly lower with γ-Toc intake than with placebo intake.
PMID 37118716 · one of two readings recorded this
VAS scores, all 10 premenstrual symptom items
increases
The VAS scores for all 10 items were significantly higher in the luteal phase than in the follicular phase
PMID 37118716 · one of two readings recorded this